Cook M, et al. - Authors examined 89 patients with non-metastatic Merkel cell carcinoma (MCC) to assess the influence of immunosuppression type on cancer-specific and overall survival (OS) among immunosuppressed individuals with MCC. They noted 53 deaths within a mean follow-up of 52 months, and calculated 30%, 55%, and 52% as 2-year progression-free survival (PFS), MCC-specific survival (MSS), and OS rates, respectively. They found that study participants with HIV/AIDS and solid organ transplant received a diagnosis of MCC at a younger age, suggesting that the risk of death from MCC varied among immunosuppression types and proposing a biological difference in host-tumor immune synergies. Recurrent MCC was noted as the major cause of mortality among immunosuppressed MCC patients.